Key Highlights

Aroa Biosurgery Limited (ASX:ARX) reported FY26 revenue of NZD 103.9 million, up 23% and above its own NZD 92-100 million guidance range.

Normalised EBITDA of NZD 12.6 million was roughly three times the NZD 4.2 million recorded in FY25, and the company posted a statutory net profit after tax of NZD 4.7 million against a prior-year loss.

FY27 guidance of NZD 115-125 million revenue but only NZD 8-11 million normalised EBITDA reflects a deliberate NZD 9 million lift in commercial spending, chiefly on the Symphony launch.

Share-price attention may centre on whether Aroa Biosurgery delivers the operational and strategic milestones described in the update.

Auckland-based soft tissue regeneration company Aroa Biosurgery reported on 26 May 2026 that revenue for the year to 31 March 2026 rose 23% to NZD 103.9 million, while normalised EBITDA roughly tripled to NZD 12.6 million. The company also swung to a statutory net profit and has guided to heavier reinvestment in FY27.

The latest financial or clinical position

A New Zealand company that reports in New Zealand dollars Aroa Biosurgery Limited (ASX:ARX) is an Auckland-headquartered medical device company that has been listed on the Australian Securities Exchange since July 2020. Every figure in its results is stated in New Zealand dollars, not Australian dollars, which matters because the two currencies are not interchangeable and the difference is material at this scale.

The company makes regenerative bioscaffolds from ovine forestomach tissue, a platform it calls AROA ECM. In plain terms, these are sheets and particulates of processed animal collagen that surgeons implant to give the body a structure on which to rebuild its own soft tissue, in complex wounds, hernia repair and breast reconstruction.

Products, programmes and commercial context

Aroa's financial year ends on 31 March, so its FY26 covers the twelve months to 31 March 2026. The results were released with a full-year presentation dated 26 May 2026, and the FY26 annual report was signed by chair James McLean and chief executive Brian Ward on the same date.

The next evidence and execution test

The headline numbers, and what EBITDA actually measures Total revenue for FY26 was NZD 103.854 million, up 23% on the NZD 84.697 million reported for FY25, or roughly 21% on a constant-currency basis, which strips out the effect of exchange-rate movements. That beat the company's own guidance range of NZD 92-100 million.

About Aroa Biosurgery

Auckland-based soft tissue regeneration company Aroa Biosurgery reported on 26 May 2026 that revenue for the year to 31 March 2026 rose 23% to NZD 103.9 million, while normalised EBITDA roughly tripled to NZD 12.6 million. The company also swung to a statutory net profit and has guided to heavier reinvestment in FY27. The company’s position remains linked to the operational, financial and strategic developments detailed in the supplied article.

What Investors May Watch Next

Delivery against reported guidance and milestones

Product adoption or clinical programme progress

Cash use, funding and commercial investment

Regulatory developments and the ARX share-price response

Risks

The company faces clinical, regulatory, commercialisation, reimbursement, competition, funding and execution risks. Guidance and development timelines are forward-looking and may change. The supplied information is a point-in-time summary and does not establish future operational or share-price performance.